NCT06772415
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
StatusTerminated
PhasePhase 1
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: The sponsor adjusted its research and development strategy Show 4 more changesShow less
- Eligibility criteria expanded, about 30 words
- Primary completion date changed from estimate of Dec 2028 to Oct 22, 2026
- Start date: Jan 8, 2025 to Jan 2, 2025
- Study sites revised (9)
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 3 to 9
- Start date changed from estimate of Jan 2025 to Jan 8, 2025
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Dose escalation: Incidence of dose-limiting toxicities (DLTs).
Timeframe: 2 years
Dose expansion: Objective response rate (ORR) evaluated by investigator based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
Timeframe: 3 Years
Secondary (7)
Incidence and severity of TEAEs.
Maximum Plasma Concentration (Cmax) of Gensci122
Time to Maximum Plasma Concentration (Tmax) of Gensci122
Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval for Gensci122
Duration of Response (DOR)
Show 2 moreShow less
Progression-free Survival (PFS)
Overall Survival (OS)
Arms and interventions
Single armExperimental
Drugs: GenSci122 tablet 50mg, GenSci122 tablet 250mg
Sites
9 sites in 1 country